Inhibiting the human GH receptor with small molecule antagonists
posted by WM Admin on 31 March 2014
Dr Jo Perry from the University of Auckland will lead a research project that seeks to discover and develop small molecule inhibitors of the growth hormone (GH) receptor and explore their use to treat breast cancer. Localised production of GH is detectable in a variety of different human cancers, including breast cancer, and this is associated with an increased risk of metastasis and reduced survival for breast cancer patients. In contrast, humans and animals born with a deficiency in the cell surface receptor for GH have a dramatically reduced, almost absent, risk of developing cancer. Consequently, inhibiting the action of GH is a promising strategy for treating breast cancer. The research team will use a specialised high-throughput assay to identify molecules that bind to the GH receptor and test these "hits" in biological assays to confirm efficacy and therapeutic potential.